BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Roshan Lal T, Seehra GK, Steward AM, Poffenberger CN, Ryan E, Tayebi N, Lopez G, Sidransky E. The natural history of type 2 Gaucher disease in the 21st century: A retrospective study. Neurology 2020;95:e2119-30. [PMID: 32764102 DOI: 10.1212/WNL.0000000000010605] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Harrar D, Mondok L, Adams S, Farias-moeller R. Zebras Seize the Day. Critical Care Clinics 2022;38:349-73. [DOI: 10.1016/j.ccc.2021.11.006] [Reference Citation Analysis]
2 Kılavuz S, Basaranoglu M, Epcacan S, Bako D, Ozer A, Donmez YN, Ceylan EI, Tukun A, Ceylaner S, Geylani H, Mungan HNO. A rare cause of hydrops fetalis in two Gaucher disease type 2 patients with a novel mutation. Metab Brain Dis. [DOI: 10.1007/s11011-022-00942-5] [Reference Citation Analysis]
3 Sam R, Ryan E, Daykin E, Sidransky E. Current and emerging pharmacotherapy for Gaucher disease in pediatric populations. Expert Opin Pharmacother 2021;22:1489-503. [PMID: 33711910 DOI: 10.1080/14656566.2021.1902989] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Daykin EC, Ryan E, Sidransky E. Diagnosing neuronopathic Gaucher disease: New considerations and challenges in assigning Gaucher phenotypes. Mol Genet Metab 2021;132:49-58. [PMID: 33483255 DOI: 10.1016/j.ymgme.2021.01.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Menkovic I, Boutin M, Alayoubi A, Curado F, Bauer P, Mercier FE, Auray-blais C. Metabolomic Study Using Time-of-Flight Mass Spectrometry Reveals Novel Urinary Biomarkers for Gaucher Disease Type 1. J Proteome Res . [DOI: 10.1021/acs.jproteome.2c00068] [Reference Citation Analysis]